Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + lenvatinib + carboplatin + etoposide
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy is being evaluated in the PELICAN Phase II clinical trial (DP-IC001) led by Imperial College London for the treatment of chemotherapy-naïve patients with advanced high-grade neuroendocrine tumors (HG-NETs). The regimen consists of an induction phase using the PD-1 inhibitor pembrolizumab in combination with carboplatin and etoposide chemotherapy, followed by a maintenance phase of pembrolizumab plus the multi-kinase inhibitor lenvatinib. Pembrolizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands (PD-L1 and PD-L2), thereby enhancing T-cell anti-tumor activity. Lenvatinib targets multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. Carboplatin and etoposide are standard cytotoxic agents that induce DNA damage and inhibit topoisomerase II, respectively, to provide synergistic anti-tumor effects.
- Brand names
- KeytrudaLenvimaParaplatin
- Other names
- PELICAN regimen
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDCD1 (Programmed cell death protein 1 receptor)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)DNAVEGFR3 (Vascular endothelial growth factor receptor 3)TOP2A (DNA topoisomerase II)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on pembrolizumab + lenvatinib + carboplatin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + lenvatinib + carboplatin + etoposide.